Cargando…

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB

Detalles Bibliográficos
Autores principales:	Uraki, Ryuta, Ito, Mutsumi, Furusawa, Yuri, Yamayoshi, Seiya, Iwatsuki-Horimoto, Kiyoko, Adachi, Eisuke, Saito, Makoto, Koga, Michiko, Tsutsumi, Takeya, Yamamoto, Shinya, Otani, Amato, Kiso, Maki, Sakai-Tagawa, Yuko, Ueki, Hiroshi, Yotsuyanagi, Hiroshi, Imai, Masaki, Kawaoka, Yoshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9729000/ https://www.ncbi.nlm.nih.gov/pubmed/36495917 http://dx.doi.org/10.1016/S1473-3099(22)00816-7

Ejemplares similares

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Transmission and re-infection of Omicron variant XBB.1.5 in hamsters
por: Halfmann, Peter J., et al.
Publicado: (2023)

Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1
por: Uraki, Ryuta, et al.
Publicado: (2023)

In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6
por: Takashita, Emi, et al.
Publicado: (2022)

Efficacy of antivirals and mRNA vaccination against an XBF clinical isolate
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

Gargle Lavage as a Safe and Sensitive Alternative to Swab Samples to Diagnose COVID-19: A Case Report in Japan
por: Saito, Makoto, et al.
Publicado: (2020)

Previous omicron infection may be protective against reinfection with omicron variant BA.5 for at least 5 months
por: Koga, Michiko, et al.
Publicado: (2023)

Evaluation of the fusion partner cell line SPYMEG for obtaining human monoclonal antibodies against influenza B virus
por: SONI, Priyanka, et al.
Publicado: (2018)

In vitro and in vivo characterization of SARS-CoV-2 strains resistant to nirmatrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Correlation Analysis between Gut Microbiota Alterations and the Cytokine Response in Patients with Coronavirus Disease during Hospitalization
por: Mizutani, Taketoshi, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the SARS-CoV-2 Omicron Subvariant BA.2
por: Takashita, Emi, et al.
Publicado: (2022)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies
por: Yasuhara, Atsuhiro, et al.
Publicado: (2017)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

A 265-Nanometer High-Power Deep-UV Light-Emitting Diode Rapidly Inactivates SARS-CoV-2 Aerosols
por: Ueki, Hiroshi, et al.
Publicado: (2022)

In SARS-CoV-2 delta variants, Spike-P681R and D950N promote membrane fusion, Spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters
por: Furusawa, Yuri, et al.
Publicado: (2023)

In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir
por: Kiso, Maki, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Differences among epitopes recognized by neutralizing antibodies induced by SARS-CoV-2 infection or COVID-19 vaccination
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Subclade 2.2.1-Specific Human Monoclonal Antibodies That Recognize an Epitope in Antigenic Site A of Influenza A(H5) Virus HA Detected between 2015 and 2018
por: Okuda, Moe, et al.
Publicado: (2019)

Effectiveness of Face Masks in Preventing Airborne Transmission of SARS-CoV-2
por: Ueki, Hiroshi, et al.
Publicado: (2020)

Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolution
por: Ravichandran, Supriya, et al.
Publicado: (2021)

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
por: Uraki, Ryuta, et al.
Publicado: (2023)

A Broadly Reactive Human Anti-hemagglutinin Stem Monoclonal Antibody That Inhibits Influenza A Virus Particle Release
por: Yamayoshi, Seiya, et al.
Publicado: (2017)

Recurring and Adaptable Binding Motifs in Broadly Neutralizing Antibodies to Influenza Virus Are Encoded on the D3-9 Segment of the Ig Gene
por: Wu, Nicholas C., et al.
Publicado: (2018)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Assessment of neutralization susceptibility of Omicron subvariants XBB.1.5 and BQ.1.1 against broad-spectrum neutralizing antibodies through epitopes mapping
por: Shah, Masaud, et al.
Publicado: (2023)

Treatment of Highly Pathogenic H7N9 Virus-Infected Mice with Baloxavir Marboxil
por: Kiso, Maki, et al.
Publicado: (2019)

Development of an Influenza Rapid Diagnostic Kit Specific for the H7 Subtype
por: Iwatsuki-Horimoto, Kiyoko, et al.
Publicado: (2018)

Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
por: Takashita, Emi, et al.
Publicado: (2022)

Characterization of Influenza A(H1N1)pdm09 Viruses Isolated in the 2018–2019 and 2019–2020 Influenza Seasons in Japan
por: Soga, Takuma, et al.
Publicado: (2023)

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron/BA.2
por: Kawaoka, Yoshihiro, et al.
Publicado: (2022)

Antigenic variants of influenza B viruses isolated in Japan during the 2017‐2018 and 2018‐2019 influenza seasons
por: Kato‐Miyashita, Sari, et al.
Publicado: (2020)

Emergence BQ.1 and BQ.1.1 as newly identified omicron subvariants: current scenario and future outlook – an update
por: Akash, Shopnil, et al.
Publicado: (2023)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_v8qva4ato8lostui3eh8qi6ne8